



The role of the conditioning regimen in allogeneic
hematopoietic stem cell transplantation is 2-fold: to deplete
the host hematopoietic and immune systems, thereby
allowing the successful establishment of donor hemato-
poietic cells, and to facilitate eradication of cancer cells in
patients with malignant disorders. A side effect of condi-
tioning therapy is the induction of cellular damage and
macrophage activation in many tissues within the body. In
this environment, donor alloreactive T cells can be more
easily sensitized to the host tissues. Both induction and
severity of graft-versus-host disease (GVHD), through con-
comitant tissue damage, may be affected by the condition-
ing regimen [1].
Interferon (IFN)- is an inflammatory cytokine pro-
duced by T cells [2] and natural killer (NK) cells [3,4] in
response to mitogenic or antigenic stimulation. The IFN-
receptor is found on a variety of tissues. IFN-, through its
cognitive receptor, exerts multiple effects on both the effector
and target cells involved in GVHD. IFN- can increase the
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ABSTRACT
Although alloreactive T cells are required for the induction of graft-versus-host disease (GVHD), other factors can
influence outcome in murine models of the disease. Lethal total body irradiation (TBI) conditioning regimens fol-
lowed by reconstitution with allogeneic lymphohematopoietic cells results in the generation of donor anti-host
cytotoxic T lymphocyte (CTL)-mediated solid organ (gut, liver, skin) destruction. In contrast, donor anti-host
CTL-mediated hematopoietic failure is the primary cause of morbidity following sublethal TBI. To determine the
role of interferon (IFN)- in graft-versus-host reactions against hematopoietic and solid organ targets, we used
IFN- knockout mice as donors in both lethal TBI and bone marrow transplantation (BMT) rescue and sublethal
TBI models. In this report, we show that CD4+ T cells from IFN- knockout (KO) mice resulted in accelerated GVHD
after lethal TBI/BMT using a single major histocompatibility class II mismatch model. In marked contrast, the use
of these same IFN- KO CD4+ donor cells in combination with sublethal TBI significantly ameliorated GVHD-
associated mortality. In these recipients, severe anemia, bone marrow aplasia, and intestinal lesions were observed in
the presence but not the absence of donor-derived IFN-. Administration of anti–IFN- antibodies to sublethally
irradiated recipients of wild-type donor cells confirmed the role of IFN- depletion in CD4+ T cell–mediated
GVHD. In conclusion, the extent of conditioning markedly affects the role of IFN- in GVHD lesions mediated by
CD4+ T cells. In models using sublethal TBI, the absence of IFN- is protective from GVHD, whereas in lethal
TBI situations, the loss is deleterious.
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T-cell sensitization phase of GVHD through upregulation
of major histocompatibility complex (MHC) classes I and II
[5,6] on allogeneic host antigen-presenting cells. At the
same time, IFN- can suppress T-cell proliferation [7] and
functional responses [8] leading to immunosuppression and
can cause lymphoid hypoplasia associated with GVHD [7].
IFN- can also act either directly or indirectly to regulate
GVHD via induction of Fas [9] or nitric oxide [10,11],
which can augment cellular cytotoxicity.
In recent studies using IFN- knockout (KO) mice
donor lymphocytes infused into full MHC mismatched
recipients conditioned with lethal total body irradiation
(TBI), we have shown that the absence of donor IFN-
accelerated GVHD [12], indicating that IFN- can be pro-
tective in lethal TBI models of GVHD. Here we extend
these findings and examine the role of IFN- in CD4+
T cell–mediated murine GVHD using different amounts of
conditioning. We observed amelioration of the GVH reac-
tion with IFN-–deficient CD4+ donor cells when single
MHC class II–mismatched recipient mice were conditioned
with sublethal TBI—although these same donor cells had
the ability to accelerate GVHD in a lethal TBI/bone mar-
row transplantation (BMT) model. The data indicate that
IFN- has a differential effect on CD4+ T cell–mediated
GVH reaction that is dependent on the extent of the condi-
tioning regimen used to prepare the recipient.
MATERIALS AND METHODS
Mice
C57Bl/6J (B6, H-2b) mice with a mutation in a single
MHC class II molecule designated B6.C.H2bm12 (bm12), B6
IFN- KO mice, and B10.BR (H-2k) mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). B6 mice
were purchased from either the Animal Production Area
(National Cancer Institute–Frederick Cancer Research and
Development Center [NCI-FCRDC]) or Jackson Labora-
tory. For some experiments, breeding pairs of C57BL/6
IFN- KO mice originally purchased from Jackson Labora-
tory were maintained at NCI-FCRDC. Recipient mice were
females, 8 to 16 weeks of age at time of transplantation.
Recipients within an individual experiment were age-
matched. Animals were cared for humanely according to the
US Public Health Policy on the Care and Use of Animals
and the Guide for the Care and Use of Laboratory Animals.
NCI-FCRDC and the University of Minnesota facilities are
accredited by the Association for Assessment and Accredita-
tion of Laboratory Animal Care International.
Induction of GVHD
For sublethal irradiation and puriﬁed lymph node (LN)
T-cell transfer involving the B6 into bm12, recipient mice
were irradiated with 600 cGy TBI by a 137Cs source. Experi-
ments were performed at both institutions (NCI-FCRDC
and University of Minnesota Cancer Center) with irradia-
tors delivering -irradiation at a dose rate of 212 cGy/min
and 85 cGy/min, respectively. Puriﬁed B6 CD4+ (106) LN
T cells were injected into bm12 recipients. Puriﬁed T-cell
preparations were obtained from single-cell suspensions of
axillary, mesenteric, and inguinal LNs treated with antibod-
ies to NK cells and CD8+ cells and passaged through a goat
anti-mouse and goat anti-rat immunoglobulin (Ig)–coated
column or with a commercial enrichment antibody cocktail
and column (R&D Systems, Minneapolis, MN). The inocu-
lum was >90% CD4+ cells as determined by ﬂow cytometry.
To determine the extent of chimerism of donor CD4+ T cells
in sublethally irradiated mice, 4 million puriﬁed CD4+ LN
cells were infused into B10.BR mice conditioned with
600 cGy (212 cGy/min). For lethal irradiation/BMT involv-
ing the B6-into-bm12 strain combination, bm12 recipients
were irradiated with 800 cGy TBI by x-ray (41 cGy/min).
Recipients were given purified B6 CD4+ (3  105) LN
T cells along with 2  107 bone marrow T cells treated with
anti-Thy 1.2 (antibody 30-H-12, rat IgG2b, provided by Dr.
David Sachs, Charlestown, MA) and complement (Nief-
fenegger, Woodland, CA).
In some experiments, bm12 mice also received neutral-
izing antibodies to IFN- [13] (clone R4-6A2) or an isotype
control (rat IgG) (PharMingen, San Diego, CA) at 300 µg/
0.5 mL phosphate-buffered saline injected twice a week,
intraperitoneally, from day 1 to 21 after CD4+ T-cell trans-
fer. This dosage of antibody has been previously shown to
inhibit IFN- responses in vivo [12,14,15].
All cell infusions were by caudal vein injection in 0.5 mL
volume. There were 8 to 10 animals per treatment group in
each experiment. Survival studies were performed 3 to 4
times. Mice were monitored and weighed weekly. All mori-
bund animals were euthanized.
Hematocrits
As an additional assessment of donor anti-host cytotoxic
T lymphocyte (CTL)-mediated bone marrow destruction,
blood was collected from mice by intraorbital puncture with
heparinized microcapillary tubes for recipient blood hemat-
ocrit determination, an indicator of bone marrow aplasia.
The tubes were centrifuged in a microhematocrit centrifuge
for 5 minutes and the packed red cell volume was deter-
mined. Hematocrits were performed on 4 to 8 animals for
each treatment group.
Flow Cytometry
Donor lymphocyte chimerism was assessed by the meas-
urement of B6 (H-2b) CD4+ cells in the spleens of B10.BR
(H-2k) mice 7 days after purified CD4+ LN cell infusion.
Splenocytes were labeled with CD4– phycoerythrin and
H-2Kb- or H-2Kk-fluorescein isothiocyanate murine anti-
bodies (mAbs), obtained from PharMingen. Irrelevant mAb
(mouse IgG2a; PharMingen) control values were subtracted
from values obtained with relevant mAbs. Ten thousand
cells per determination were analyzed by 2-color flow
cytometry using a FACScan (Becton Dickinson, San Jose,
CA). Cells were gated for lymphocytes based on forward-
and side-scatter settings.
Granulocyte/Macrophage–Colony-Forming Units 
Effects on hematopoietic progenitors were assessed by
the measurement of myeloid progenitors in the bone marrow
and spleens of recipient mice. Mice were assessed at various
time points. For each time point, 3 to 5 mice per group were
analyzed. Spleen and bone marrow cells were washed and
suspended in Iscove’s modiﬁed Dulbecco’s medium with 5%
fetal bovine serum, 1% L-glutamine, and antibiotics. Cells
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were plated in 1.1% methylcellulose (Fisher Scientiﬁc, Pitts-
burgh, PA) in triplicate 35-mm petri dishes (Falcon; Becton
Dickinson, Lincoln Park, NJ) at a concentration of 0.5 to
1.0  106 spleen cells or 0.5 to 1.0  105 bone marrow cells
per plate. Colony formation was stimulated with 10 ng/mL
recombinant murine granulocyte/macrophage–colony-
stimulating factor (rmGM-CSF) (Amgen, Thousand Oaks,
CA) and 20 ng/mL recombinant murine interleukin (rmIL)-3
(Biological Response Modiﬁers Program Repository, Freder-
ick, MD). Plates were incubated at 37°C for 7 days in 5%
CO2 with 100% humidity. Colonies (>50 cells) were enumer-
ated on a Nikon stereo microscope (Nikon, Melville, NY).
Histology
To assess mice for evidence of GVHD-induced tissue
destruction, tissues from recipient mice were placed in
10% formalin, embedded in paraffin, sectioned at 5 µm,
and stained with hematoxylin and eosin. Small intestines
were prepared for histological evaluation using the Swiss
roll technique. Tissue samples were collected 14 days after
sublethal irradiation and 13 days after infusion of CD4+-
enriched LN cells. Liver, small intestine, and colon sec-
tions prepared from 3 animals per treatment group were
assessed by a veterinary pathologist. Histopathologic
changes were graded as minimal, mild, moderate, or severe
and as focal, multifocal, or diffuse.
Statistical Analyses
Survival data were plotted by the Kaplan-Meier method
and analyzed by the log-rank test. Two-way analysis of vari-
ance was used to compare time and treatment. Group com-
parisons were made with Student t test. A P value of <0.05
was considered signiﬁcant.
RESULTS
IFN-–Deficient CD4+ T Cells Accelerate GVHD
Morbidity in Lethally Irradiated MHC Class II Only
Disparate Recipients
We have previously reported that the absence of IFN-,
which is produced by donor splenocytes, accelerates mortality
in 2 distinct fully allogeneic mouse strain combinations
involving lethal TBI and bone marrow cell rescue: the
BALB/c (H-2d) into B6 (H-2b) model, which is disparate at
the MHC and multiple minor histocompatibility antigens,
and the B6 into B10.BR (H-2k) model, which is disparate
only at MHC [12]. To determine whether donor IFN- KO
regulates CD4+ T cell–mediated GVHD mortality, we trans-
planted puriﬁed CD4+ LN T cells from either wild-type or
IFN- KO B6 donors, along with T-cell–depleted bone mar-
row cells, into lethally irradiated (800 cGy; x-ray) bm12 (dis-
parate at class II) recipients. When 300,000 CD4+ cells were
transplanted, there was a signiﬁcant acceleration of GVHD-
associated death in the absence of donor IFN- (Figure 1A).
Profound weight loss was observed before mortality in recipi-
ents of IFN- KO CD4+ cells (Figure 1B). These observa-
tions were confirmed in experiments using another condi-
tioning source (900 cGy by 137Cs; data not shown). This
result demonstrates that IFN- is protective in CD4+ T cell–
mediated GVHD in models using lethal TBI and supports
previous studies using whole populations of T cells [12].
Absence of Donor IFN- Results in Amelioration of
CD4+ T-Cell GVHD in a Sublethal TBI Model
B6 CD4+ T cells mediate profound bone marrow aplasia
and subsequent mortality when transferred into sublethally
irradiated bm12 mice [16]. To determine the role of IFN-
on T cell–mediated bone marrow failure, we used the sub-
lethal TBI model for the CD4+ T cell–mediated GVH reac-
tion. Recipient (bm12) mice received a sublethal dose of
TBI (600 cGy) followed by adoptive transfer of CD4+ LN
T cells from either wild-type or IFN- KO mice. Although
we initially predicted that IFN-–deficient donor T cells
would accelerate morbidity because of increases in allospe-
ciﬁc GVH reactions as seen when lethal TBI was used, sur-
prisingly, the absence of IFN- in CD4+ T cells markedly
ameliorated GVH-associated mortality (Figure 2). To
demonstrate that the effects of using the IFN- KO cells
were not due to developmental changes in the T-cell com-
partment of these mice, we performed the same studies
using wild-type T cells and neutralizing antibodies to IFN-.
Administration of neutralizing IFN- antibody to recipients
of wild-type donor cells also resulted in protection from
GVHD and confirmed the observations with IFN-–defi-
cient T cells (Figure 2). These results indicated that in
marked contrast to the data using lethal TBI/BMT, the
loss of IFN- is protective in sublethal models of GVHD.
Failure of IFN-–deﬁcient CD4+ T cells to engraft in
recipients following sublethal TBI would be consistent with
improved outcome and 1 potential mechanism by which
IFN- could potentiate GVHD. To assess this possibility,
we determined the extent of donor T-cell chimerism in
recipients after sublethal TBI. Because antibodies are not
available to discriminate between B6 donor and bm12 recip-
ient T cells, we infused B6 wild-type or IFN- KO CD4+-
enriched LN cells into MHC class I– and class II–disparate
recipients (B10.BR) after sublethal TBI. IFN- KO CD4+
donor cells were present at a higher number in the spleens
at day 7 after cell transfer compared with wild-type CD4+
donor cells in the recipient mice (Table 1). Taken together,
these results suggest that IFN- plays a critical role in pro-
moting CD4+ T cell–mediated mortality in GVHD models
using sublethal TBI without compromising donor T-cell
chimerism.
Loss of IFN- Production by CD4+ T Cells Confers
Protection From Allospecific Induction of Anemia
and Bone Marrow Aplasia in Sublethal TBI Models
Mortality is associated with profound anemia in the
CD4+/MHC class II–disparate sublethal TBI model. Sub-
lethally irradiated recipient mice were anemic 14 days after
CD4+ wild-type (B6) T-cell infusions as determined by
hematocrits (Table 2). However, recipients of donor IFN-
KO CD4+ T cells exhibited only a mild anemia associated
with the TBI and did not signiﬁcantly differ from control
mice that received irradiation without subsequent CD4+-
enriched LN-cell transfer.
Hematologic status of bone marrow and spleen were
assessed at various time periods early posttransfer in recipi-
ents of CD4+-enriched LN T cells to confirm the absence
of hematopoietic cell destruction by IFN-–deficient cells.
Total nucleated cell content and committed hemato-
poietic progenitors as measured by the colony-forming
IFN- and MHC Class II–Associated GVHD
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units–granulocyte/macrophage (CFU-GM) assay were
examined. Recipients of wild-type CD4+-enriched LN
T cells exhibited a severe loss of cells (Figure 3) in the
bone marrow beginning on day 9 after transfer and in the
spleen by day 13. This was also associated with a profound
loss of myeloid progenitors (Figure 4). In contrast, recipi-
ents of IFN- KO CD4+-enriched LN T cells exhibited no
inhibition of myeloid progenitor recovery and only a mild
depression in bone marrow cellularity compared with simi-
larly irradiated animals. The depression in splenic cellular-
ity and myeloid progenitors observed in recipients of wild-
type donor cells was not observed in recipients of IFN-
KO donor cells. Overall, these findings suggest that allore-
active CD4+ T cells induce a loss of myeloid progenitors
and subsequent progressive bone marrow and splenic apla-
sia, primarily through an IFN-–dependent mechanism.
Loss of IFN- Production by CD4+ T Cells Confers
Protection From Intestinal Lesions in Sublethal TBI,
MHC Class II–Disparate Model of GHVD
Although morbidity is primarily associated with hemato-
poietic failure in the bm12 recipients of sublethal TBI and
CD4+ T cells, it has been shown that the gut and liver are
also targets for GVHD in this model [17]. In our studies,
histological examination of the large and small intestines of
the animals on day 13 after cell transfer revealed evidence of
GVHD-associated pathology (Table 3 and Figure 5). In the
small intestine, recipients of wild-type CD4+-enriched LN
cells had mild multifocal crypt cell hyperplasia with the pres-
ence of apoptotic crypt epithelium. The lamina propria had
inﬁltrates of mononuclear cells and occasional neutrophils.
In comparison, only 1 of 3 recipients of IFN- KO CD4+-
Figure 2. Interferon (IFN)- ameliorates graft-versus-host (GVH)
mortality in recipients of sublethal total body irradiation (TBI) and
CD4+ T cells. Recipient mice (bm12) received 600 cGy TBI followed
by administration of B6 or B6 IFN- knockout (KO) donor T cells.
Neutralizing IFN- antibody or irrelevant rat immunoglobulin (Ig) was
administered as described in “Materials and Methods.” One million
(106) donor CD4+-enriched lymph node cells (LNCs) (>95% purity)
were administered to recipients (n = 8). Survival of recipients of donor
IFN- KO cells or B6 donor cells and IFN- antibody is signiﬁcantly
prolonged (P < .05 and P < .0005, respectively) compared with control.
WT indicates wild type.
Table 1. Donor CD4+-Enriched T-Cell Chimerism in Spleens of
MHC-Disparate Recipient Mice*
Donor CD4+ T Cells
Donor Recipient Frequency, % Per Spleen, 104
B6 wild type B10.BR 0.13 ± 0.7 1.6 ± 0.9
B6 interferon- B10.BR 2.89 ± 0.41† 39.7 ± 0.6†
knockout
*B10.BR recipient mice received 600 cGy total body irradiation fol-
lowed by administration of 4  106 B6 or B6 interferon- knockout
donor CD4+-enriched lymph node cells (>90% purity). No CD8+ cells
were detected in the cell inocula. Spleens were analyzed for the pres-
ence of donor-derived T cells 7 days after cell transfer. Each treat-
ment group contained 4 animals. MHC indicates major histocompati-
bility complex. 
†Signiﬁcantly different from B6 wild type, P < .001 (Student t test).
Figure 1. Interferon (IFN)- is protective for recipients of lethal total body irradiation (TBI)/bone marrow transplantation (BMT) in CD4+-medi-
ated acute lethal graft-versus-host disease (GVHD). A, Recipient mice (bm12) received 800 cGy TBI followed by administration of donor
T-cell–depleted bone marrow cells alone (alloBMT) or in combination with 3  105 B6 wild-type (WT) or B6 IFN- knockout (KO) CD4+-
enriched lymph node cells (n = 8/group). GVHD morbidity was accelerated in recipients of IFN-–deﬁcient donor cells (P < .0001). B, Weights of
the animals that received lethal TBI followed by BMT as depicted in A. Recipients of IFN- KO CD4+ lymph node cells exhibited signiﬁcant (P <
.001) weight loss at day 14 after cell transfer relative to recipients of WT cells.
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enriched LN cells had minimal crypt apoptosis of the small
intestine. No inflammation or crypt hyperplasia was
observed in these animals. The small intestines of recipients
of sublethal TBI without T-cell infusion appeared normal at
this time point. Similar observations were made in the colon
on day 13 after LN-cell transfer. All recipients of sublethal
TBI and wild-type CD4+-enriched LN cells displayed multi-
focal crypt cell hyperplasia and apoptosis in colonic crypts,
whereas the recipients of IFN- KO CD4+-enriched LN
cells and sublethal TBI controls appeared normal. No
signiﬁcant differences between the 3 treatment groups were
observed in representative liver sections of these animals
(data not shown). These results show that in this sublethal
TBI model involving a single MHC class II mismatch,
intestinal GVHD is also associated with the ability of donor
cells to produce IFN-. Thus, even solid organ toxicity in
CD4+-mediated GVHD is ameliorated in the absence of
IFN- in sublethal TBI models.
DISCUSSION
The results presented here demonstrate that IFN-
plays both critical and opposing roles in CD4+ T cell–
mediated GVH reactions, depending on the extent of condi-
tioning of the recipient. In mice conditioned with lethal
TBI followed by MHC class II–disparate BMT, IFN- is
protective. However, in mice conditioned with sublethal
TBI followed by adoptive transfer of MHC class II–dis-
parate CD4+ T cells, IFN- production by donor cells is
deleterious.
The role of IFN- in alloresponsiveness is complex and
at times contradictory. In addition to a direct inhibition of
hematopoiesis by IFN-, myelosuppression by IFN- may
be augmented through the induction of Fas [9] and MHC
[5,6]. Elevated MHC surface expression could enhance tar-
geting of hematopoietic stem cells and progenitors for allo-
geneic T-cell destruction by pathways that include Fas/FasL.
Whereas MHC class I molecules are expressed on all nucle-
Table 2. Hematologic Parameters Following Induction of GVH Reaction*
HCT, %
Experiment and Donor Antibody Treatment Recipient Day 14 Day 28
Experiment 1
B6 WT Rat IgG bm12 13.2 ± 4.0 NS
B6 IFN- KO Rat IgG bm12 36.1 ± 4.5† 46.2 ± 4.4
B6 WT Anti–IFN- bm12 24.4 ± 4.2‡ 40.3 ± 7.6
Experiment 2
B6 WT None bm12 15.6 ± 1.5 NT
B6 IFN- KO None bm12 35.3 ± 1.3† NT
None None bm12 39.0 ± 2.2† NT
*Recipient mice received 600 cGy total body irradiation (TBI) followed by administration of B6 or B6 interferon (IFN)- KO donor T cells.
Neutralizing IFN- antibody or irrelevant rat immunoglobulin was administered as described in “Materials and Methods.” Results from representa-
tive experiments are presented. One million (106) donor CD4+-enriched lymph node cells (LNC) (>95% purity) were administered to bm12 recipi-
ents. Control animals received TBI but did not receive LNCs. Each treatment group contained 4 to 8 animals. GVH indicates graft-versus-host;
HCT, hematocrit; WT, wild type; Ig, immunoglobulin; NS, no survivors; KO, knockout; NT, not tested.
†Signiﬁcantly different from B6, P < .0005 (Student t test). 
‡Signiﬁcantly different from B6, P < .001 (Student t test).
Figure 3. Severe bone marrow and splenic aplasia in recipients of wild-type (WT) but not interferon (IFN)-–deﬁcient major histocompatibility
complex (MHC)–disparate CD4+-enriched lymph node cells (LNCs). Recipient bm12 mice received 600 cGy total body irradiation (TBI) 1 day
before infusion of B6 () or B6 IFN- knockout (KO) () donor T cells. Control animals () received TBI without subsequent cell transfer. The
bone marrow and spleen cellularities were analyzed on days 6, 9, and 13 after CD4+ T-cell transfer. Progressive loss of bone marrow (A) and splenic
(B) total nucleated cell content is observed following sublethal TBI and administration of WT but not IFN-–deﬁcient MHC-disparate LNCs.
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ated cells, MHC class II molecules are transiently expressed
on developing hematopoietic precursors [18] and subse-
quently expressed on classical antigen-presenting cells.
Donor CD4+ T cells, capable of producing IFN-, suppress
allogeneic hematopoiesis in an MHC class II–specific
action, because it has been shown that engraftment of
donor-derived bone marrow cells is not impaired [16]. In
this report, we ﬁnd that donor-derived IFN- also promotes
MHC class II–speciﬁc allogeneic hematopoietic and gut tis-
sue destruction after sublethal TBI. Interestingly, absence of
IFN- does not significantly protect against allospecific
CD8+ T cell–mediated hematopoietic aplasia in a sublethal
TBI model (data not shown), suggesting that CD8+ T cells
may use other pathways in GVHD.
MHC class II incompatibility alone is sufficient to
induce intestinal GVHD [19-21], although lethality from
GVHD, presumably from gut damage, requires lethal TBI
in these MHC class II–disparate transplantations [21]. The
combination of irradiation-induced tissue damage may
induce tumor necrosis factor and other mediators that result
in GVHD without the need for IFN-.
We and others have investigated the role of IFN- in
GVHD. Brok and colleagues [22,23] have shown that the
administration of IFN- in a full MHC-disparate lethal
TBI/BMT model can ameliorate GVHD. Conversely, it has
been shown that neutralization of systemic IFN- or the use
of IFN-–deﬁcient donor cells in lethal TBI/BMT models—
with major or minor histocompatibility antigen differ-
ences—accelerates disease [12,24,25]. Together, these studies
demonstrate that donor-derived IFN- has a protective func-
tion in acute GVHD, and the addition of exogenous IFN-
potentiates this activity. In contrast, Ellison et al. [26] used a
parent-into-F1 hybrid model to investigate the role of IFN-.
They found that IFN- was important for mortality in their
model, although recipients of IFN-–deﬁcient T cells devel-
oped disease that was more characteristic of chronic GVHD.
Their model differs from the previous studies in 2 aspects.
The recipients in that model were not conditioned with TBI
and the recipient T cells could not reject donor grafts; both
aspects may have contributed to their ﬁndings. In agreement
with our observations with IFN-–deﬁcient CD4+ T cells and
sublethal irradiation, Ellison and colleagues not only
Figure 4. Wild-type (WT) but not interferon (IFN)-–deficient major histocompatibility complex (MHC)-disparate CD4+-enriched lymph
node cells (LNCs) suppress host hematopoietic progenitors. Recipient bm12 mice received 600 cGy total body irradiation (TBI) 1 day before
infusion of B6 () or B6 IFN- knockout (KO) () donor T cells. Control animals () received TBI without subsequent cell transfer. The
hematopoietic progenitors in the bone marrow and spleen were analyzed on days 6, 9, and 13 after CD4+ T-cell transfer. Progressive loss of bone
marrow (A) and splenic (B) colony-forming units–granulocyte/macrophage (CFU-GM) is observed following sublethal TBI and administration
of WT but not IFN-–deficient MHC-disparate LNCs. ND, not detected.
Table 3. Histopathologic Evaluation of Intestinal Tissues on Day 13 Following Induction of GVH Reaction*
WT CD4+ LNC IFN- KO CD4+ LNC Irradiation Control
Animal 1 2 3 1 2 3 1 2 3
Small intestine N N N N N N N
Crypt cell hyperplasia 2+ MF 2+ MF 2+ MF
Inflammation, subacute 2+ MF 1+ MF 1+ MF
Apoptosis, crypt 2+ MF 2+ MF 2+ MF 1+ MF
Globular leukocytes 1+ MF 1+ MF
Colon N N N N N N
Crypt cell hyperplasia 1+ MF 1+ MF 1+ MF
Inflammation, subacute 1+ MF
Apoptosis, crypt 1+ MF 1+ MF 2+ MF
*Grading information: 1+, minimal; 2+, mild; 3+, moderate; 4+, severe; N, no signiﬁcant lesions; MF, multifocal. GVH indicates graft-versus-
host; WT, wild type; LNC, lymph node cell; IFN, interferon; KO, knockout.
L.A. Welniak et al.
610
Figure 5. Representative photomicrographs showing protection from graft-versus-host (GVH)-associated intestinal damage with interferon (IFN)-–
deﬁcient CD4+ donor T cells after sublethal total body irradiation (TBI). Recipient bm12 mice received 600 cGy TBI 1 day before infusion of B6 or
B6 IFN- knockout (KO) donor T cells. Control animals received TBI without subsequent cell transfer. The small intestine and colon were col-
lected and analyzed on day 13 after CD4+ T-cell transfer. A, Small intestine from a recipient of B6 WT CD4+ cells illustrating crypt cell hyperplasia
(c), apoptotic crypt cells, and inﬂammation (i). B, Small intestine from a recipient of B6 IFN- KO CD4+ cells with minimal crypt cell apoptosis.
C, Small intestine from a recipient of sublethal TBI without subsequent cell transfer. No lesions. D, Colon from a recipient of B6 wild-type (WT)
CD4+ cells illustrating diffuse crypt cell hyperplasia. E, Colon from a recipient of B6 IFN- KO CD4+ cells. No lesions. F, Colon from a recipient
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observed diminished acute GVHD but greater expansion of
donor-derived IFN-–deficient CD4+ as well as CD8+
T cells. Using a different model of acute GVHD, we have
extended their observations to demonstrate that under non-
myeloablative preparative regimens, IFN- worsens acute
GVHD. Further, we have found that the opposing roles of
IFN- under different conditioning regimens are due to its
activity in donor CD4+ and not CD8+ T cells.
Although we demonstrate that the opposing roles of
IFN- in acute GVHD are dependent on the intensity of
the conditioning regimen, this phenomenon is still not well
understood. Induction of inﬂammatory cytokines by high-
dose irradiation may be able to compensate for the immuno-
stimulatory activities of IFN-. Loss of an autocrine
immunosuppressive activity would then predominate as the
mechanism for accelerated morbidity in the lethal
TBI/BMT model. We have shown that adoptively trans-
ferred B6 IFN- KO CD4+ T cells are present in greater
numbers in the spleens of B10.BR mice prepared with sub-
lethal TBI (Table 1) than are cells from wild-type donors.
Although we cannot rule out that the absence of donor
IFN- provides an advantage in evading rejection, 2 lines of
evidence support increased survival of IFN- KO cells.
First, in the article by Ellison et al. [26], using a parent-into-
F1 model where recipient NK cells but not T cells can
reject donor cells, there is greater expansion of donor-
derived IFN- KO CD4+ T cells compared with cells from
wild-type donors. Second, IFN- KO splenocytes have been
reported to exhibit sustained proliferation in response to
mitogen and alloantigen [27].
The use of nonmyeloablative conditioning regimens for
BMT has recently been under intense scrutiny. However,
compared with transplants prepared with high-dose therapy,
there is a greater concern for the establishment of donor
chimerism. In the nonmyeloablative transplantation setting,
the absence or blockade of IFN- in collaboration with
MHC class II–mismatched grafts may diminish intestinal
GVHD but at the expense of anti-host hematopoietic action.
In a similar scenario, IFN- may enhance CD4+-enriched
delayed lymphocyte infusion activity against both normal
and leukemic host hematopoietic progenitor cells [28,29].
In conclusion, acute lethal GVHD is accelerated in the
absence of IFN- in an MHC class II–mismatched lethal
TBI/BMT model. However, the absence of donor IFN-
results in amelioration of GVH-associated mortality when
sublethal levels of TBI are used as conditioning therapy.
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